Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomideReportar como inadecuado

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Neuro-Oncology

, Volume 126, Issue 2, pp 347–354

First Online: 07 November 2015Received: 14 June 2015Accepted: 24 October 2015DOI: 10.1007-s11060-015-1975-y

Cite this article as: Koekkoek, J.A.F., Dirven, L., Heimans, J.J. et al. J Neurooncol 2016 126: 347. doi:10.1007-s11060-015-1975-y


We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma LGG treated with temozolomide TMZ chemotherapy. We retrospectively reviewed adult patients with a progressive LGG and uncontrolled epilepsy in two hospitals VUmc Amsterdam; MCH The Hague, who received chemotherapy with TMZ between 2002 and 2014. End points were a ≥50 % seizure reduction and MRI response 6, 12 and 18 months mo after the start of TMZ, and their relation with progression-free survival PFS and overall survival OS. We identified 53 patients who met the inclusion criteria. Seizure reduction was an independent prognostic factor for both PFS HR 0.38; 95 % CI 0.19–0.73; p = 0.004 and OS HR 0.39; 95 % CI 0.18–0.85; p = 0.018 after 6mo, adjusting for age and histopathological diagnosis, as well as after 12 and 18mo. Patients with an objective radiological response showed a better OS median 87.5mo; 95 % CI 62.0–112.9 than patients without a response median 34.4mo; 95 % CI 26.1–42.6; p = 0.046 after 12mo. However, after 6 and 18mo OS was similar in patients with and without a response on MRI. Seizure reduction is an early and consistent prognostic marker for survival after treatment with TMZ, that seems to precede the radiological response. Therefore, seizure reduction may serve as a surrogate marker for tumor response.

KeywordsSeizures Chemotherapy Temozolomide Primary brain tumor Glioma Electronic supplementary materialThe online version of this article doi:10.1007-s11060-015-1975-y contains supplementary material, which is available to authorized users.

Download fulltext PDF



Documentos relacionados